Giandomenico Roviello1, Navid Sobhani2,3, Silvia Paola Corona2, Alberto D'Angelo4. 1. Department of Health Sciences, University of Florence, Viale Pieraccini, 6, 50139, Florence, Italy. giandomenicoroviello@hotmail.it. 2. Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada Di Fiume 447, 34149, Trieste, Italy. 3. Breast Cancer Unit, ASST Cremona, Viale Concordia 1, 26100, Cremona, Italy. 4. Department of Biology and Biochemistry, University of Bath, Bath, B2 7AY, UK.
Abstract
INTRODUCTION: Abiraterone acetate plus prednisone is approved in metastatic castration-resistant prostate cancer. There is some evidence in favour of the steroid switch from prednisone to dexamethasone in patients who progressed whilst on abiraterone acetate plus prednisone or prednisolone. MATERIALS AND METHODS: The aim of this review is to discuss the results from the clinical studies available, examining potential mechanisms of action and patient selection criteria for this treatment option. RESULTS: A total of four studies were evaluated. Among possible eligibility criteria for steroid switch, we found: PSA progression without any radiological or clinical progression during abiraterone acetate + prednisone; no high-grade adverse events related to CYP-17 inhibition; and unfitness for chemotherapy or radium-223. CONCLUSION: Although large randomized prospective trials are warranted, steroid switch seems to offer a good option for certain patients treated with abiraterone acetate plus prednisone or prednisolone.
INTRODUCTION:Abiraterone acetate plus prednisone is approved in metastatic castration-resistant prostate cancer. There is some evidence in favour of the steroid switch from prednisone to dexamethasone in patients who progressed whilst on abiraterone acetate plus prednisone or prednisolone. MATERIALS AND METHODS: The aim of this review is to discuss the results from the clinical studies available, examining potential mechanisms of action and patient selection criteria for this treatment option. RESULTS: A total of four studies were evaluated. Among possible eligibility criteria for steroid switch, we found: PSA progression without any radiological or clinical progression during abiraterone acetate + prednisone; no high-grade adverse events related to CYP-17 inhibition; and unfitness for chemotherapy or radium-223. CONCLUSION: Although large randomized prospective trials are warranted, steroid switch seems to offer a good option for certain patients treated with abiraterone acetate plus prednisone or prednisolone.
Authors: K Nishimura; N Nonomura; E Satoh; Y Harada; M Nakayama; T Tokizane; T Fukui; Y Ono; H Inoue; M Shin; Y Tsujimoto; H Takayama; K Aozasa; A Okuyama Journal: J Natl Cancer Inst Date: 2001-11-21 Impact factor: 13.506
Authors: Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf Journal: N Engl J Med Date: 2012-12-10 Impact factor: 91.245
Authors: M E Taplin; G J Bubley; T D Shuster; M E Frantz; A E Spooner; G K Ogata; H N Keer; S P Balk Journal: N Engl J Med Date: 1995-05-25 Impact factor: 91.245
Authors: Nuria Romero-Laorden; Rebeca Lozano; Anuradha Jayaram; Fernando López-Campos; Maria I Saez; Alvaro Montesa; Ana Gutierrez-Pecharoman; Rosa Villatoro; Bernardo Herrera; Raquel Correa; Adriana Rosero; María I Pacheco; Teresa Garcés; Ylenia Cendón; Ma Paz Nombela; Floortje Van de Poll; Gala Grau; Leticia Rivera; Pedro P López; Juan-Jesús Cruz; David Lorente; Gerhardt Attard; Elena Castro; David Olmos Journal: Br J Cancer Date: 2018-08-21 Impact factor: 7.640